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Abstract
Background: Genome-wide association studies (GWAS) represent the current frontier in pharmacogenomics.
Thousands of subjects of Caucasian ancestry have been included in previous GWAS investigating antidepressant
response. GWAS focused on this phenotype are lacking in Asian populations.
Methods: A sample of 109 major depressive disorder (MDD) patients of Korean origin in antidepressant treatment was
collected. Phenotypes were response and remission according to the Hamilton Rating Scale for Depression (HRSD).
Genome-wide genotyping was performed using the Illumina Human Omni2.5-8 platform. The same phenotypes were
used in the STAR*D level 1 (n = 1677) for independent replication. In order to corroborate findings and increase the
comparability between the two datasets, three levels of analysis (SNPs, genes and pathways) were carried out.
Bonferroni correction, permutations, and replication across samples were used to reduce the risk of false positives.
Results: Among the genes replicated across the two samples (permutated p < 0.05 in both of them), CTNNA3
appeared promising. The inorganic cation transmembrane transporter activity pathway (GO:0022890) was associated
with antidepressant response in both samples (p = 2.9e-5 and p = 0.001 in the Korean and STAR*D samples,
respectively) and this pathway included CACNA1A, CACNA1C, and CACNB2 genes.
Conclusions: The present study supported the involvement of genes coding for subunits of L-type voltage-gated
calcium channel in antidepressant efficacy across different ethnicities but replication of findings is required before
any definitive statement.




Antidepressant response was demonstrated to have a
relevant genetic component, exemplified by the contri-
bution of common single nucleotide polymorphisms
(SNPs) that was estimated to explain 0.42 of variance in
this phenotype [1]. Three main GWAS (genome-wide
association studies) investigated antidepressant response
in samples of mainly Caucasian ancestry [2–4] and sev-
eral re-analyses [5] or meta-analysis [6, 7] were per-
formed on these data.
Less GWAS data are available in regard to antidepres-
sant efficacy in samples of Asian ancestry compared to
Caucasian populations and previous studies performed
only SNP-level analysis.
One previous GWAS on Japanese patients suggested
the possible involvement of CUX1 (Cut-Like Homeobox
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1) gene that codes for a member of the homeodomain
family of DNA binding proteins [8]. It may regulate gene
expression, morphogenesis, and differentiation and it
may also play a role in the cell cycle progression.
To the best of our knowledge, only another GWAS
investigated antidepressant response in a Korean
population and it reported two SNPs in the AUTS2
(Autism Susceptibility Candidate 2) gene (rs7785360 and
rs12698828) as genome-wide significant [9]. AUTS2
codes for a nuclear protein that is expressed in the
central nervous system in humans, especially in some
hippocampal areas and it has been implicated in neuro-
developmental disorders, schizoaffective and bipolar
affective disorders [9].
Another recent GWAS included a relevant number of
Asian subjects especially from Taiwan and secondly from
Japan and it did not report genome-wide significant re-
sults. Among the top genes, NRG1 (neuregulin-1) is par-
ticularly interesting since this gene is involved in many
aspects of brain development and it was associated with
schizophrenia risk [10].
Methodological considerations
Recent studies suggested that genes (and not only SNPs)
should be investigated in GWAS since they represent
the functional units of genome. Molecular pathways are
more complex functional units that represent the follow-
ing step in the development of multi-marker analysis in
GWAS. Several methods have been applied to identify
molecular pathways that may be involved in antidepres-
sant efficacy, and they can be classified according to the
criteria used to define gene sets, to select p values to be
considered in the analysis and the statistics used to as-
sess the significance of each gene set [11]. Gene sets can
be defined a priori including pathways reported by avail-
able databases (e.g. KEGG, BioCarta) or according to the
over-representation of some gene sets in the data. In
detail, genes including trait-associated SNPs can be
grouped in functionally-enriched sets according to phys-
ical and genetic interaction data, predicted protein inter-
action, pathway and molecular interaction data as
implemented by GeneMANIA [12]. After the definition
of gene sets, several methods are available to test their
significance in GWAS. Gene-set statistics can take into
account the most significant p value in each gene (e.g.
[13]) or SNPs with p under a defined threshold (e.g. [14,
15]) and a permutation-based procedure is usually ap-
plied to test the significance of each gene set against the
null hypothesis. Another possible method takes into
consideration all the p values in each gene set and it as-
signs a score to each gene set using the Z-statistic [16].
Starting from the assumption that only some gene sets
may be relevant to a particular trait, we performed a
pathway analysis based on two steps. Firstly, we
performed an over-representation analysis using Gene-
MANIA [12] in order to identify functionally-enriched
gene sets in our data and secondly enriched gene sets
were investigated comparing the distribution of inde-
pendent SNPs with p values under defined thresholds
within each target gene set to a random gene set. The
same two-step method was previously applied [17].
Aims of the present study
Given that antidepressant response was less investigated
by GWAS in Asian samples compared to Caucasian
ones, the present GWAS aimed to investigate anti-
depressant efficacy in a relatively small but homogenous
sample of depressed patients of Korean origin. The ana-
lysis was based on three levels, i.e. SNPs, genes and
pathways in order to not overlook the correlation struc-
tures among multiple SNPs within genes and multiple
genes within pathways. This is the first GWAS that per-
formed also gene- and pathway-level analyses on an
Asian population. Finally, this study directly compared
findings obtained in the Korean GWAS with those from
the STAR*D (Sequenced Treatment Alternatives to
Relieve Depression) GWAS (mainly including subjects of
white non-Hispanic origin) in order to identify shared





Patients were consecutively collected among patients ad-
mitted to the psychiatric unit of the Department of
Psychiatry, Catholic University of Korea College of
Medicine, Seoul, Korea. Inclusion criteria were: 1) age
between 18–80, 2) current episode of major depression
in patients with major depressive disorder (MDD) diag-
nosis, 3) current antidepressant pharmacological treat-
ment. Exclusion criteria were: 1) current or recent
substance abuse (at least during the past 6 months), 2)
severe or unstable medical condition that may impair
evaluations, 3) neurological disorders, 4) non-Asian eth-
nicity, 5) other treatments than antidepressants with the
exception of anti-anxiety drugs, 6) poor understanding
or fluency of Korean language, 7) mental retardation.
Clinical and socio-demographic data were collected by
interviews or revision of the clinical charts. Diagnosis of
MDD and current depressive episode were performed
according to the Diagnostic and Statistical Manual of
mental disorders IV, text revised (DSM-IV-TR) criteria
by the Semi-structured clinical interview for DSM-IV
(SCID-I) [18]. Symptom severity was evaluated by the
Hamilton Rating Scale for Depression (HRSD17) [19].
All patients were evaluated for symptom severity at ad-
mission and discharge (observation period of 4–6
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weeks). Evaluations were performed by trained inter-
viewers blind to genetic data. Anxiolytics (alprazolam,
lorazepam, clonazepam or buspirone) were the only
concomitant psychotropic medications allowed. The
clinical-demographic characteristics of the included pa-
tients are summarized in Additional file 1: Table S1.
Ethics, consent and permissions
All the patients were informed in detail about the aims
and the procedures of the study and they signed a writ-
ten informed consent prior inclusion into the study. The
protocol and the written informed consent were ap-
proved by the local ethical committee (Catholic Medical
Center, Clinical Research Coordinator Center; approval
number HC10TISI0031).
STAR*D sample
The sample under investigation was retrieved from
the public available Sequenced Treatment Alternatives
to Relieve Depression (STAR*D) study, level 1. De-
tailed descriptions of the study design and study
population are detailed elsewhere [20]. In brief, non
psychotic MDD (DSM-IV criteria) patients with age
between 18 and 75 years were enrolled from primary
care or psychiatric outpatient clinics and a current
17-item Hamilton Depression Rating score of ≥14 by
independent raters was obtained. All patients received
a systematic assessment battery at entry and were
treated by a psychiatrist (trained to deliver care and
measure outcomes in patients with MDD) using a
series of model practice procedures consistent with
expert recommendations. Severity of depression was
assessed using the 16-item Quick Inventory of De-
pressive Symptomatology-Clinician Rated (QIDS-C)
[21] at baseline, weeks 2, 4, 6, 9, and 12. All patients
received citalopram in level 1. Concomitant treat-
ments for current general medical conditions (as part
of ongoing clinical care), for associated symptoms of
depression (e.g., sleep, anxiety, and agitation), and for
citalopram side effects (e.g., sexual dysfunction) were
permitted on the basis of clinical judgment. Stimulants,
anticonvulsants, antipsychotics, alprazolam, non-protocol
antidepressants (except trazodone ≤200 mg at bedtime
for insomnia), and depression-targeted psychother-
apies were proscribed [22]. The clinical-demographic
characteristics of the patients are summarized in
Additional file 1: Table S1.
In order to avoid possible biases due to the consid-
eration of mild depression forms, we only included
patients with an entry QIDS-SR score greater or
equal to 10 (significantly depressed) that corresponds
to a Hamilton Depression Rating score (HDRS)
greater or equal to 14.
Definition of phenotypes
According to standard criteria, in the Korean sample re-
sponse was defined as a ≥50 % symptoms reduction
(HRSD17 score) from baseline to discharge and remis-
sion was defined as the HRSD17 score ≤7 at discharge.
In the STAR*D sample, response was defined as a ≥50 %
symptoms reduction (QIDS-SR score) from baseline to
week 12 while remission was defined as the QIDS-SR
score ≤5 at week 12. The last observation carried for-
ward method (LOCF) was applied when baseline and at
least one post-baseline observation were available, ac-
cording to previous studies that analyzed STAR*D data
[22]. The choice to not use week 6 response and remis-
sion in the STAR*D (that would correspond to the time
end-point in the Korean sample) was due to the obser-
vation that the most part of STAR*D patients reached
response and remission at or after week 8 [22]. Some
clinical differences between the two samples (e.g. in-
patient vs. outpatient status) were probably responsible
for the observed similar response and remission rates at
week 6 in the Korean sample and week 12 in the
STAR*D (see Additional file 1: Table S1).
Genotyping
Korean sample
Genotyping was performed using Illumina Human
Omni2.5-8 platform. The HumanOmni2.5-8 BeadChip
delivers comprehensive coverage of both common and
rare SNP content from the 1000 Genomes Project
(1kGP; MAF > 2.5 %), designed to be maximally inform-
ative for diverse world populations. It is able to identify
2,379,855 polymorphisms. The scan protocol followed
the standard Illumina procedures using Illumina BeadX-
press Reader. The microarray data was analyzed with
GenomeStudio V2011.1 and GT module 1.9.4 using de-
fault analysis settings. Each SNP is analyzed independ-
ently to cluster and identify genotypes. Genotype calls
are generated by comparing experimental data with
those in the supplied cluster file(*.egt). Calls are gener-
ally highly accurate and unambiguous for high quality
samples.
STAR*D sample
STAR*D patients were genotyped using the Affymetrix
Human Mapping 500 k Array Set. The Mapping 500 K
Array Set is comprised of two arrays, each capable of
genotyping on average 250,000 SNPs. One array uses the
Nsp I restriction enzyme (~262,000 SNPs), while the
second uses Sty I (~238,000 SNPs). Together, the family
of GeneChip Mapping products offers solutions for
genotyping ~500,000 SNPs. Given that the number of
SNPs genotyped in this sample is lower compared to
that available in the Korean sample (500,000 vs.
2,379,855) and different platforms were used, only a
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Quality control of genome-wide data was performed ac-
cording to the following criteria in both samples. SNPs
were pruned out according to linkage disequilibrium
(r2 > 0.8), minor allele frequency (MAF < 0.01), individ-
ual genotyping rate (>0.05 missing genotypes) and
Hardy-Weinberg equilibrium (p < 0.001). Results of qual-
ity control are shown by QQ plots in Additional file 2:
Figure S1. Identity-by-descent (IBD) analysis was used to
identify related subjects (IBD > 0.1875 [23]) in the
STAR*D. 21 pairs of related subjects were identified (ac-
cordingly to what previous reported [24]) and one sub-
ject per pair was excluded from the analysis.
Individual polymorphisms association analysis
The analysis of individual SNPs association with the di-
chotomous phenotypes (remission and response) was
performed by logistic regression models, including as co-
variates potential stratification factors as discussed in
paragraph 2.3.3. PLINK software was used for these ana-
lysis [25].
SNPs with p < 0.05 in the Korean sample were tested
in the STAR*D and those showing p < 0.05 in both sam-
ples were used to select genes that were included in the
functional enrichment analysis and gene set enrichment
analysis (GSEA). The direction of the association was
not a considered a criteria to select SNPs to include in
the following levels of analysis since probable relevant
pharmacogenetic associations were found to show op-
posite direction in different populations (e.g. 5-HTTLPR
in the SLC6A4 gene [26]). We underline that SNP-level
analysis was exploratory only and it mainly aimed to
identify signals to include in the following steps of the
study (gene- and pathway-level analysis).
Selection of covariates
We considered sex and age as covariates in both sam-
ples. The entry level of HRSD17 (Korean sample) and
QIDS-SR (STAR*D) was also used as covariate for re-
mission only since the variable highly affected this
phenotype in both samples (p = 8.03e-7 and p = 1.75e-10
in the Korean sample and STAR*D, respectively) while it
did not affect response. In the STAR*D also ancestry
was included among covariates. Briefly, a complete
agglomerative clustering was applied, based on a multi-
dimensional scaling of a matrix of pairwise identity-by-
state (IBS) values between samples, and clusters were
defined on the base of the pairwise population concord-
ance test (PPC < 0.0001, −-cluster and –-ppc options in
Plink according to [25]). In the Korean sample all
subjects were of Korean origin thus the inclusion of the
covariate ancestry was not required.
Functional enrichment analysis
The SNPs with p < 0.05 in both the Korean and STAR*D
samples for each phenotype were annotated (PLINK
function –annotate) using a 20 Kbp window upstream
and downstream of each gene. In order to take into ac-
count all the possible genes related with the phenotypes
under analysis we enriched the obtained gene lists using
Cytoscape [27] and the GeneMania [28] plugin. Gene-
Mania uses a large database of functional interaction
networks from multiple organisms and each related gene
is traceable to the source network used to make the pre-
diction [28]. This plugin also identifies the biological
processes in which these genes play a role, on the basis
of the Gene Ontology international database [29]. Gene
Ontology biological processes are defined as pathways in
the present paper since they can be used as functional
units to perform a pathway analysis despite the descrip-
tion of the dynamics or dependencies that would be re-
quired to fully describe a pathway was not performed
yet in the context of the Gene Ontology project.
At the end of the process 83 and 77 genes including
SNPs with p < 0.05 in both samples or interacting with
them were identified for remission and response, re-
spectively. These genes play a role in 10 and 7 biological
pathways (Gene Ontology [29]), respectively. Graphic
representation of genes and pathways are shown in
Additional file 3: Figure S2. Additional file 4: Table S2
and Additional file 5: Table S3 report the characteristics
of genes and pathways under analysis for response and
remission phenotypes, respectively. These genes and
pathways were then used for the gene set enrichment
analysis (GSEA).
Gene set enrichment analysis (GSEA)
As previously described [30], results referred to individ-
ual SNPs can be analyzed as organized in pathways by
comparing the distribution of SNPs with p value under a
defined threshold between the index pathway and a ran-
dom pathway (Fisher exact test). The same method can
be applied to genes, i.e. the distribution of SNPs with p
under a defined threshold within a candidate gene is
compared with that of a random gene.
In the present study, genes included in each of the
pathways selected in 2.3.4 were firstly imputed using IM-
PUTE2 (http://mathgen.stats.ox.ac.uk/impute/impute_
v2.html) and 1000 Genomes data (NCBI Build 36
(dbSNP b126) for the STAR*D and GRCh37 Build for
the Korean sample) as reference panel. Imputed SNPs
were pruned according to linkage disequilibrium (r2 ≥
0.8) and poor imputation quality (info < 0.8). Secondly,
variations showing p < 0.05 in each pathway of interest
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were tested for a significant different distribution (Fisher
exact test) compared to a random pathway. Each ran-
dom pathway was matched with the index pathway in
terms of number of SNPs within it and intragenic pos-
ition of the SNPs but with random distribution within
the whole genome.
The same procedure was performed for each gene in-
cluded in the candidate pathways, i.e. variations showing
p < 0.05 in each gene of interest were tested for a signifi-
cant different distribution (Fisher exact test) compared
to a random gene. Nominal p values under 0.05 were
permutated randomly re-assigning the SNPs in the two
groups 100,000 times for each pathway/gene. The
present method based on a Fisher exact test avoids the
restriction of the focus on the “top” p values of the path-
way/gene, and thus it is able to detect more subtle sig-
nals compared to methods that are based on the
smallest individual p values in the pathway [31]. In fact,
methods based on Fisher’s exact test resulted to be
among those with the highest power in such type of ana-
lysis [32]. We finally underline that GSEA investigated a
different hypothesis compared to functional enrichment,
since it did not search for interactions among genes but
it tested if the distribution of SNPs with p value below a
threshold in the gene set compared to what observed by
chance (i.e. in a random set) was different. Further, the
genes included in the functional enrichment analysis
were selected only according to the criteria of including
at least one SNP with p < 0.05 in both samples while our
GSEA took into account the p values of all the SNPs
within each gene.
Multiple testing correction
Multiple testing corrections were performed according
to the Bonferroni correction and permutation. The p
value for a significant individual SNP result was set at
0.05/585,693 = 8e-8 in the Korean sample for remission
and response. The liberal p threshold of 0.05 was used
to select individual SNPs to be tested in the replication
sample (STAR*D).
The significance of results of gene- and pathway-based
analyses was tested by 100,000 permutations after a first
selection based on the Bonferroni correction (p = 0.05/
83 = 0.0006 for gene-based analysis; p = 0.05/10 = 0.005
and p = 0.05/7 = 0.007 for pathway analysis, remission
and response phenotypes, respectively).
Power of the study
When considering an intermediate MAF of 0.20 and the
response phenotype, the Korean sample provided a
power of 0.72 for a SNP with OR = 2.84, while the
STAR*D sample provided a power of 0.61 when consid-
ering a SNP with OR = 1.26 (data referred to SNPs
rs2112460 and rs2299267, respectively, were used for
power estimation).
For the purpose of SNP-level power analysis a nominal
p value of 0.05 was considered because this analysis was
aimed to be an exploratory analysis to provide data for
subsequent analyses (gene- and pathway-base analyses).
Genetic power calculator was used to estimate the
power of the study [33].
For gene- and pathway-based analyses the power was
estimated using G*Power 3.1 [34]. When considering the
significant gene/pathway with the smallest number of
total SNPs (the MTRF1L gene in the STAR*D sample
that included only 26 SNPs) we had a power of about
0.80 setting alpha to 0.0006 (Bonferroni corrected p) if
the proportion of SNPs with p under the significance
threshold was 29 % more than expected by chance and a
power of 0.95 in the observed case (the proportion of
SNPs with p under the significance threshold was 33 %
more than expected by chance). When considering the
gene/pathway with the highest number of total SNPs
(the GO:0022890 pathway in the Korean sample that in-
cluded 7531 SNPs) we had a power of about 0.80 setting
alpha to 0.007 (Bonferroni corrected p) if the proportion
of SNPs with p under the significance threshold was
1.9 % more than expected by chance and of a power
0.76 in the observed case (the proportion of SNPs with p
under the significance threshold was 1.3 % more than
expected by chance).
Results
Individual SNP association analysis
The analysis of the remission phenotype provided 25,976
SNPs with p < 0.05 in the Korean sample, but no one
survived after the Bonferroni correction. Of these 25,976
SNPs, 1455 (Additional file 6: Table S4) were available in
the STAR*D dataset and 76 (Additional file 7: Table S5)
showed p < 0.05 also in this sample; the top six SNPs for
remission are reported in Table 1A.
The analysis of the response phenotype provided
24,606 SNPs with p < 0.05 in the Korean sample, but no
one survived after the Bonferroni correction. Of these
24,606 SNPs, 1392 (Additional file 8: Table S6) were
available in the STAR*D dataset and 77 (Additional file
9: Table S7) showed p < 0.05 also in this sample; the top
six SNPs for response are reported in Table 1B.
Manhattan plots referred to remission and response
phenotypes in the Korean sample are shown in Add-
itional file 10: Figure S3 and top SNPs (p < 10e-05) in
this sample are reported in Additional file 11: Table S8.
Gene association analysis
The association analysis between the 84 genes harbored
by the SNPs showing p < 0.05 in both the two samples
and remission showed several replicated genes that
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survived after permutations: ATP/GTP Binding Protein-
Like 1 (AGBL1), Cytochrome B5 Type A (Microsomal)
(CYB5A), Mitochondrial Translational Release Factor 1-
Like (MTRF1L) and Regulator Of G-Protein Signaling 22
(RGS22) (Table 2A). For the response phenotype the fol-
lowing genes (tot. genes = 77) survived after permuta-
tions in both samples: Catenin (Cadherin-Associated
Protein), Alpha 3 (CTNNA3) and Heparan Sulfate 6-O-
Sulfotransferase 3 (HS6ST3) (Table 2B).
Pathway association analysis
The association analysis between the molecular path-
ways that are harbored by the replicated genes and re-
sponse showed only one pathway that survived after
permutations in both samples: GO:0022890 (Gene
Ontology ID), relative to inorganic cation transmem-
brane transporter activity. The investigated genes
pertaining to this pathway are Calcium Channel,
Voltage-Dependent, P/Q Type, Alpha 1A Subunit (CAC-
NA1A), Calcium Channel, Voltage-Dependent, P/Q
Type, Alpha 1C Subunit (CACNA1C), Calcium Channel,
Voltage-Dependent, Beta 1 Subunit (CACNB1), Calcium
Channel, Voltage-Dependent, Beta 2 Subunit (CACNB2),
Cytochrome B5 Type A (Microsomal) (CYB5A), Solute
Carrier Family 4 (Sodium Bicarbonate Cotransporter),
Member 4 (SLC4A4), Solute Carrier Family 4 (Sodium
Bicarbonate Cotransporter), Member 5 (SLC4A5), Sol-
ute Carrier Family 4 (Sodium Bicarbonate Cotranspor-
ter), Member 7 (SLC4A7), Solute Carrier Family 6
(Neurotransmitter Transporter, Serotonin), Member 4
(SLC6A4), Solute Carrier Family 6 (Neurotransmitter
Transporter, Serotonin), Member 2 (SLC6A2). Table 3
reports the characteristics and statistics of this path-
way. No pathway survived in both samples after
multiple-testing correction when the remission pheno-
type was analyzed.
Table 1 Description of the 6 best SNP for remission (A) and response (B) in both the analyzed samples
Korean sample STAR*D
SNP Chromosome base pair Gene MAF Odds ratio Statistics p MAF Odds ratio Statistics p
A
rs9315310 13 NBEA (165 Kbp) 0.28 3.67 3.1.32 <0.00001 0.21 1.21 2.112 0.034700
35351431
rs672170 6 RGS17 0.45 3.48 3.130 0.001748 0.36 1.18 2.155 0.031140
153345185
rs2532560 12 PARP11 (179 Kbp) 0.14 0.16 −3.079 0.002075 0.20 1.20 2.002 0.045270
4161871
rs2831440 21 N6ATM1 (800 Kbp) 0.39 3.53 3.045 0.002327 0.32 0.79 −3.126 0.001774
29428098
rs766127 6 RGS17 |MTRF1L |FBXO5 0.42 2.89 2.954 0.003134 0.30 1.21 2.374 0.017580
153313832
rs4737771 8 CRH (100 Kbp) 0.20 0.24 −2.943 0.003246 0.12 1.26 2.005 0.044920
67192379
B
rs49411 3 FHIT 0.50 0.36 −3.292 0.0009939 0.49 0.85 −2.277 0.022760
59757575
rs10997242 10 CTNNA3 0.29 0.32 −3.025 0.0024890 0.16 1.30 2.788 0.005303
68336295
rs16873129 7 RAPGEF5 0.17 0.32 −2.912 0.0035970 0.07 1.32 2.103 0.035470
22145084
rs2299267 7 PON2 0.39 0.46 −2.858 0.0042650 0.17 1.26 2.486 0.012930
95061921
rs2112460 19 CACNA1A 0.21 2.84 2.759 0.0057920 0.48 1.19 2.497 0.012530
13590412
rs521093 1 EPS8L3 (62 Kbp) 0.10 5.13 2.728 0.0063760 0.20 1.21 2.096 0.036040
110368230
When a SNP is localized in an intergenic region, the nearest gene is reported with distance in parenthesis
MAF minor allele frequency
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Discussion
The present study investigated the genetic markers of
antidepressant response/remission in two independent
genome-wide datasets through SNP-, gene- and
pathway-based analyses. The original sample included
Korean MDD subjects and the STAR*D study served as
independent replication on a different ethnicity. Despite
the limited sample size of the Korean sample, we under-
line that relatively limited data exist on Asian popula-
tions [8, 10] and only one previous study was performed
on a Korean sample [9]. The use of three levels of ana-
lysis, i.e. SNPs, genes and molecular pathways, was ex-
pected to reduce the risk of false positive findings
despite our results should be considered as exploratory
given the sample size issue. The number of SNPs that
showed p < 0.05 in both GWAS was approximately the
same expected by chance, but SNP-level analysis was
not intended to discover associated SNPs but to provide
a relaxed criteria to select findings for subsequent levels
of analysis. Gene- and pathway-based analyses were cor-
rected for multiple-testing (Bonferroni correction and
permutations), thus providing an acceptable support for
the results of these analysis that can be hints for future
studies.
SNP-level analysis did not retrieve any genome-wide
significant result, but some potential interesting findings
emerged when looking at the SNPs showing p < 0.05 in
both the samples. The top finding for remission was
rs9315310 which nearest gene is NBEA (neurobeachin).
NBEA codes a multidomain scaffolding protein primarily
expressed in the brain where it is involved in trafficking
of vesicles containing neurotransmitter receptors, specif-
ically GABA and glutamate receptors [35, 36]. No previ-
ous study suggested the involvement of this gene in
antidepressant efficacy or MDD, but the glutamatergic
and gabaergic systems are known to be involved in anti-
depressant mechanisms of action [37, 38]. Another inter-
esting finding for remission was rs4737771 that is
located 100 Kbp far from the CRH (corticotropin releas-
ing hormone) gene. Indeed, the inhibition of CRH gene
expression by antidepressant drugs was demonstrated
[39] and polymorphisms within CRHR1 and CRHR2
(CRH receptors 1 and 2) were associated with anti-
depressant response [26]. The other SNPs with p < 0.05
Table 2 Genes that resulted associated with remission (A) and response (B) in both the analyzed samples
Korean sample STAR*D
Gene Gene full name SNPs with p < 0.05 SNPs (tot N) Permuted p SNPs with p < 0.05 SNPs (tot N) Permuted p




268 (7 %) 3454 (92 %) 3722 <0.00001 65 (9 %) 601 (90 %) 656 8.9e-5
CYB5A Cytochrome B5 Type
A (Microsomal)
216 (58 %) 152 (41 %) 368 <0.00001 25 (37 %) 41 (62 %) 66 3.9e-5
MTRF1L Mitochondrial Translational
Release Factor 1-Like
85 (47 %) 95 (52 %) 180 <0.00001 10 (38 %) 16 (61 %) 26 0.0003
RGS22 Regulator Of G-Protein
Signaling 22




446 (6 %) 6628 (93 %) 7074 <0.00001 118 (11 %) 952 (88 %) 1070 <0.00001
HS6ST3 Heparan Sulfate
6-O-Sulfotransferase 3
305 (15 %) 1626 (84 %) 1931 <0.00001 50 (14 %) 298 (85 %) 348 8.9e-5
True/False are referred to the number (and percentage) of SNPs with p < 0.05 in the considered subset. The expected number (due to chance) of N true
corresponds to 5 % of the total
Table 3 Results pertaining to the only molecular pathway that was replicated in both samples (N tot. molecular pathways = 7) for
the response phenotype
Korean sample STAR*D
GO ID Pathway name SNPs with p < 0.05 SNPs (tot N) Permuted p SNPs with p < 0.05 SNPs (tot N) Permuted p




478 (6 %) 7053 (93 %) 7531 2.9e-5 123 (8 %) 1317 (91 %) 1440 0.001
True/False are referred to the number (and percentage) of SNPs showing association with p < 0.05 in the considered subset. The expected number (due to
chance) of N true corresponds to 5 % of the total
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in both samples (for remission) are shown in Additional
file 7: Table S5 and we underline the presence of the fol-
lowing genes: 1) SLC6A3 (solute carrier family 6 mem-
ber gene 3), that codes for the dopamine transporter and
other polymorphisms within it were previously associ-
ated with antidepressant response by candidate gene
studies [40, 41]); 2) CACNA1A (calcium channel,
voltage-dependent, P/Q type, alpha 1A subunit) and
CACNB2 (calcium channel, voltage-dependent, beta 2
subunit), that were demonstrated as the top signals in a
GWAS investigating risk loci with shared effects among
major psychiatric disorders [42]; and 3) NRG3 (neurore-
gulin 3) gene that is a ligand of ERBB4 which signaling
is involved in neurotransmission, synaptic plasticity, and
ketamine antidepressant action [43]. Interestingly, a sig-
nal in NRG1 was recently identified as promising marker
of antidepressant response by a meta-analysis [10].
The most interesting SNPs showing p < 0.05 for re-
sponse in both samples were in the CTNNA3 (catenin
(cadherin-associated protein), alpha 3) and CACNA1A
genes (Table 1).
The CTNNA3 (catenin alpha-3) gene was associated
with the risk of schizophrenia [44] and intracellular signal-
ing through beta-catenin translocation and AKT/PKB
pathways have implicated in antidepressant-induced hip-
pocampal cell proliferation [45]. Most importantly, a
suggestive signal in the CTNNA3 gene was recently asso-
ciated with antidepressant response in a GWAS including
mainly patients of Asian ancestry [10]. Among SNPs with
p < 0.05 for response (Additional file 9: Table S7), a SNP
near to SLC6A3 was again present (see results referred to
the remission phenotype). Further, the intronic rs582854
polymorphism in the serotonin receptor 2A (HTR2A)
gene was only at 17 Kbp from a previous signal found in
this gene [46] and in linkage disequilibrium (r2 = 0.6 and
D’ = 0.97) with rs6313 and rs6311 in the CEU population
(1000 Genomes phase 3 data). HTR2A is a replicated can-
didate gene for involvement in antidepressant response,
rs6313-rs6311 were associated with this phenotype by
candidate gene studies [26] and rs6313 was confirmed by
a recent meta-analysis [47].
Compared to a previous GWAS of antidepressant re-
sponse in a Japanese sample reporting the CUX1 rs365836
and rs201522 as top findings [8], we found that weak
signals came from this gene (remission: rs10240601 p =
0.028; rs73412036 p = 0.039; rs12668172 p = 0.026;
rs11971570 p = 0.025; response: rs2694159 p = 0.040). The
CUX1 rs365836 and rs201522 are ~ 99 far from rs2694159
and ~ 88 Kbp from rs11971570, despite no evidence of
linkage disequilibrium among these SNPs was found in
Asian populations according to 1000 Genomes data. No
CUX1 SNP with p < 0.05 was found in the STAR*D.
Only one previous GWAS investigated antidepressant
response in a Korean population [9] and two SNPs in
the AUTS2 gene (rs7785360 and rs12698828) were gen-
ome-wide significant. In the present study several SNPs in
the AUTS2 gene showed p values < 0.05 in the Korean sam-
ple (remission: rs17141924 p = 0.01; rs4718974 p = 0.03; re-
sponse: rs77393802 p = 0.03; rs10950209 p = 0.008;
rs10234816 p = 0.04), and one SNP showed p < 0.05 in both
samples (rs7459368: p = 0.0007 and p = 0.03 in the STAR*D
and the Korean sample, respectively), but these SNPs are
about 700 Kbp from the previous findings and no evidence
of linkage disequilibrium exists among them.
Gene-based analysis and pathway analysis provided
some additional findings compared to SNP-level ana-
lysis. AGBL1, CYB5A, MTRF1L, and RGS22 emerged
from SNP-based analysis and they were associated with
remission also in gene-based analysis, as well as for
CTNNA3 and HS6ST3 genes and response. A role of
CTNNA3 in antidepressant response is supported by lit-
erature as we discussed, while no previous study sup-
porting the involvement of the other findings of gene-
based analysis was published. Anyway, several of these
genes are related to processes involved in cell survival,
proliferation and migration, that are encompassed in the
neural plasticity theory of depression [48]. AGBL1 has a
role in controlling the length of the polyglutamate side
chains on tubulin and this process is critical for neuronal
survival and the lack of such control results in neurode-
generation in mice [38]. HS6ST3 generates structures re-
quired for interactions between heparan sulfate and a
variety of proteins. These interactions are implicated in
cell proliferation, differentiation, adhesion and migration
[49]. RGS22 (regulator of G-protein signaling 22) has
been implicated in the processes of cell migration in
cancer [48]. CYB5A (cytochrome B5 type A (micro-
somal)) was related to autophagy induction, concomitant
with reduced proliferation and migration/invasion in
cancer cells [50].
Despite their limited evidence due the small sample
size, some genes were significant (p < 0.0006) in the Ko-
rean sample but they were not replicated in the STAR*D.
They included NR3C2 (nuclear receptor subfamily 3
group C member 2), SLC6A4 (solute carrier family 6
member 4), HTR2A, SLC25A4 (solute carrier family 25
member 4), SLC6A3, and CACNA1A for both response
and remission. NR3C2 codes for mineralocorticoid re-
ceptor 1 (MR1) and antidepressants were shown to
modulate MR hormone-binding [51] and expression [52]
in the context of the corticosteroid receptor hypothesis
of depression. SLC6A4 is a known candidate gene for in-
volvement in antidepressant response [26] even if the
most studied polymorphism is an insertion/deletion thus
it was not available in this sample. Quantitative prote-
omic analyses on mice hippocampal tissue implicated
SLC25A4 product in serotonergic antidepressant action
[53]. HTR2A, SLC6A3, and CACNA1A are discussed
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elsewhere in this paragraph. HTR2A (response, p = 0.03),
SLC6A3 and CACNA1A (remission, p = 0.05 and p =
0.03, respectively) gene-based analyses showed non-
significant trends in the STAR*D.
The only pathway that survived multiple-test correc-
tion in both samples was GO:0022890 related to
inorganic cation transmembrane transporter activity
(Table 3). This pathway included several genes coding
for calcium channels (CACNA1A, CACNA1C, CACNB1,
CACNB2). As we discussed above, polymorphisms in
CACNA1A and CACNB2 were demonstrated to be
trans-diagnostic markers of major psychiatric disorders
[42]. CACNB1 expression was modified in response to
nortriptyline in hippocampal mice tissues [53]. Preclin-
ical studies supported a role of CACNA1C in the patho-
genesis of mood disorders [54] and the gene was
associated with MDD, bipolar disorder, schizophrenia
and autism spectrum disorders [55]. These genes code
for subunits of the L-type voltage-gated calcium channel
(LTCC) that is mainly involved in coupling of cell mem-
brane depolarization to transient increase of the mem-
brane permeability for calcium, leading to potential
changes in intracellular signaling, gene transcription,
and synaptic plasticity. These functions of LTCC in-
volved brain regions that are pivotal in MDD pathogen-
esis such as the hippocampus and amygdale. LTCC
antagonists were suggested as potential antidepressant
molecules alone or in combination with SSRIs [55] and
imipramine was also demonstrated to modulate Ca(2+)
intracellular rise in rat hippocampus [56].
In the Korean sample only, the GO:0015844 pathway
(monoamine transport) survived after multiple-testing
correction for both response and remission (p = 7.00e-05
and p = 0.0006, respectively). This result is in line with
the gene-based analysis in the Korean sample, but it was
not replicated and thus poorly relevant given the small
sample size.
Some limitations of the present study should be consid-
ered. First, the limited size of the Korean sample, thus the
present findings should be interpreted cautiously. Quite
large samples of white race were previously collected for
GWAS on antidepressant efficacy, while less data are avail-
able on samples of Asian ancestry [8–10], thus this study
can contribute to expand our knowledge in the field and
provide data for future meta-analysis (no meta-analysis in-
cluding only subjects of Asian ancestry was performed yet).
The risk of false positive findings was faced through the use
of multi-level analysis (SNP-, gene, and pathway-based),
permutation, and replication to corroborate findings. The
imputation of data only at level of gene- and pathway ana-
lyses have limited the comparability of the two datasets at
SNP-level, but this choice was based on resource/benefit ra-
tio considerations. Indeed, it would have been more re-
source consuming and a Korean reference panel provided
by the 1000 Genomes or HapMap projects is not available.
The Korean population was demonstrated to have a dis-
tinctive genetic architecture [57] and decreased imputation
quality due to the lack of a Korean reference panel [58] can
be balanced in the context of multimarker tests (gene- and
pathway-based tests) while it could affect the results at SNP
level. The use of the STAR*D as replication sample can be
seen as a further limitation because subjects were mainly of
non-Hispanic white origin. Some polymorphisms were
found overrepresented in certain ancestry groups [59] but
similar genes have been often implicated in the same
phenotype across populations (e.g. rheumatoid arthritis [60]
and also antidepressant response [26]). Given that the
present study was not limited to the analysis of individual
polymorphisms but included a gene-based analysis and
pathway analysis, this approach is expected to increase the
comparability between the two datasets. Anyway, we exam-
ined the MAFs of the SNPs reported in Table 1 across the
main ethnic groups of the STAR*D (white non-Hispanic,
white Hispanic and African-American). For 5/12 SNPs and
9/12 SNPs the MAF difference was less than 10 % and less
than 15 %, respectively. Other stratification factors between
the two samples should be considered, such as treatment
and other clinical variables. Regarding treatment, it was not
standardized, but the most part (76 %) of patients included
in the Korean sample were treated with the SSRI paroxetine
and all patients in STAR*D level 1 were treated with the
SSRI citalopram. Inter-class pharmacogenetic differences
between antidepressant drugs are possible [61] while differ-
ences among drugs of the same class are less known. Any-
way, non-standardized treatment provides the advantage of
being more similar to real clinical settings. Treatment dur-
ation was also not standardized, but it was within a narrow
range of 4–6 weeks. Finally, the Fisher’s exact test method
that we applied to perform the GSEA was based on the dis-
tribution of SNPs with two a priori defined thresholds (0.05
and 0.01), thus we cannot exclude that the use of different
p thresholds would have provided higher statistical power.
On the other hand, this method avoided the restriction of
the focus on the “top” findings of the pathway/gene and it
provided an internal term of comparison in the real data
(the random pathway) to test the null hypothesis.
Conclusions
The present study replicated the association of several
genes and the inorganic cation transmembrane transporter
activity pathway (GO:0022890) with antidepressant efficacy
in a Korean GWAS and the STAR*D. Among promising
genes, we reported CACNA1A, CACNB2, CACNA1C,
CACNB2, CTNNA3 and other genes involved in cell adhe-
sion, migration, survival and proliferation (AGBL1, HS6ST3,
RGS22, CYB5A). Given the small size of the Korean sample,
these findings should be considered cautiously and inde-
pendent replication is required.
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cation but not sharing them in public. STAR*D data are
available from NIMH genetics (https://www.nimhgen-
etics.org/) via submission of a research project.
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